sipuleucel-T

The federal agency said Provenge, known generically as sipuleucel-T, is "reasonable and necessary" for use in men with certain cases of metastatic prostate cancer.

Medicare to Cover Drug for Prostate Cancer Thomas M. Burton 2011

By way of example, take the case of sipuleucel-T, one of a class of "molecularly targeted therapies" that "are revolutionizing the treatment of cancer."

Cancer Care's Rationers 2011

PROVENGE® sipuleucel-T; fund new clinical trials for PROVENGE and other product candidates;

Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 - Yahoo! Finance 2011

Dendreon is a biotechnology company whose first product, PROVENGE (sipuleucel-T) ("Provenge"), was approved by the U.S. Food and Drug Administration in April 2010.

unknown title 2011

DNDN's first product, Provenge (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010.

unknown title 2011

PROVENGE® sipuleucel-T; fund new clinical trials for PROVENGE and other product candidates;

Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 - Yahoo! Finance 2011

Provenge (sipuleucel-T) for the treatment of castration-resistant metastatic prostate cancer.

SeekingAlpha.com: Home Page Joseph Krueger 2010

Provenge (sipuleucel-T) for the treatment of castration-resistant metastatic prostate cancer.

Healthcare Sector and Stocks Analysis from Seeking Alpha Joseph Krueger 2010

Provenge (sipuleucel-T) for the treatment of castration-resistant metastatic prostate cancer.

Healthcare Sector and Stocks Analysis from Seeking Alpha Joseph Krueger 2010

Provenge (sipuleucel-T) for the treatment of castration-resistant metastatic prostate cancer.

SeekingAlpha.com: Home Page Joseph Krueger 2010